Literature DB >> 29987607

Trends in the Diagnosis of Phyllodes Tumors and Fibroadenomas Before and After Release of WHO Classification Standards.

Jenny Chang1, Laura Denham2, Eun Kyu Dong1, Kirollos Malek1, Sharon S Lum3.   

Abstract

BACKGROUND: In 2012, the World Health Organization (WHO) released diagnostic criteria for grading phyllodes tumors based on histologic features. This study sought to examine the application of the WHO criteria and the changing epidemiology of fibroepithelial tumors.
METHODS: A retrospective review of surgically excised fibroepithelial lesions from 2007 to 2017 at a single tertiary care institution was conducted. Data regarding the WHO criteria (tumor border, stromal cellularity, stromal cell atypia, stromal overgrowth, mitotic activity) and traditional descriptors (leaf-like architecture, periductal stromal condensation) were collected. Clinical and pathologic characteristics of cases with diagnoses determined before and after 2012 were compared.
RESULTS: During the study period, 305 fibroepithelial tumors were identified. No significant differences were observed in terms of mean age, race/ethnicity, presenting symptoms, or method of diagnosis between cases diagnosed before and after 2012. After 2012, the findings showed statistically significant increases in reporting of WHO and traditional histologic features, a decrease in diagnoses of fibroadenomas (85.9% [116/135] before vs 70.0% [119/170] after 2012), and an increase in benign phyllodes tumors (0% [0/135] before vs 12.9% [22/170] after 2012). Patients with a diagnosis of benign phyllodes tumors were significantly younger than those with a diagnosis of borderline, malignant, or non-graded phyllodes tumors (mean age, 25.7 ± 10.6 vs 52.8 ± 9.9, 40.7 ± 24, 46.3 ± 1.5 years, respectively; p = 0.006).
CONCLUSIONS: The expanding use of the 2012 WHO criteria has been accompanied by an increased diagnostic frequency of benign phyllodes tumors and a decrease in fibroadenomas. As fibroepithelial diagnoses become more distinct, evidence-based management recommendations for less virulent phyllodes diagnoses should be developed.

Entities:  

Mesh:

Year:  2018        PMID: 29987607     DOI: 10.1245/s10434-018-6622-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  3 in total

1.  Preoperative interventional artery embolization for the treatment of a giant malignant phyllodes tumor: A case report.

Authors:  Yue Tian; Linlin Liu; Liang Chen; Shengdi Zhao; Ruijun Su; Wenzhu Zhang; Aimei Jiang; Wenlin Chen; Fei Ge
Journal:  Mol Clin Oncol       Date:  2021-05-11

2.  Core needle biopsy in fibroepithelial tumors: predicting factors for phyllodes tumors.

Authors:  Yedda Nunes Reis; Jonathan Yugo Maesaka; Carlos Shimizu; José Maria Soares-Júnior; Edmund Chada Baracat; José Roberto Filassi
Journal:  Clinics (Sao Paulo)       Date:  2021-04-16       Impact factor: 2.365

3.  Retrospective study of malignant phyllodes tumors of the breast: Younger age, prior fibroadenoma surgery, malignant heterologous elements and surgical margins may predict recurrence.

Authors:  Yang Li; Yixuan Song; Ronggang Lang; Lu Shi; Shuang Gao; Hong Liu; Ping Wang
Journal:  Breast       Date:  2021-03-17       Impact factor: 4.380

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.